{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:02:56Z","timestamp":1789675376092,"version":"4.0.1"},"reference-count":188,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T00:00:00Z","timestamp":1787443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["32570850"],"award-info":[{"award-number":["32570850"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s10495-026-02403-1","type":"journal-article","created":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:06:42Z","timestamp":1787504802000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials"],"prefix":"10.1007","volume":"31","author":[{"given":"Xiao-Han","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Chun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umm E.","family":"Laila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Rong","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Ying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Dong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,23]]},"reference":[{"issue":"3","key":"2403_CR1","doi-asserted-by":"publisher","first-page":"222","DOI":"10.14712\/23362936.2021.20","volume":"122","author":"S Sen","year":"2021","unstructured":"Sen S, Sen S, Kumari MG, Khan S, Singh S (2021) Oral malignant melanoma: a case report. Prague Med Rep 122(3):222\u2013227. https:\/\/doi.org\/10.14712\/23362936.2021.20","journal-title":"Prague Med Rep"},{"issue":"13","key":"2403_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.986214","volume":"19","author":"JY Liu","year":"2022","unstructured":"Liu JY, Liu LP, Li Z, Luo YW, Liang F (2022) The role of cuproptosis-related gene in the classification and prognosis of melanoma. Front Immunol 19(13):986214. https:\/\/doi.org\/10.3389\/fimmu.2022.986214","journal-title":"Front Immunol"},{"issue":"1","key":"2403_CR3","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","volume":"23","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A (2015) Melanoma. Nat Rev Dis Primers 23(1):15003. https:\/\/doi.org\/10.1038\/nrdp.2015.3","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"2403_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1615\/CritRevEukaryotGeneExpr.2020028454","volume":"30","author":"B Ahmed","year":"2020","unstructured":"Ahmed B, Qadir MI, Ghafoor S (2020) Malignant melanoma: skin cancer-diagnosis, prevention, and treatment. Crit Rev Eukaryot Gene Expr 30(4):291\u2013297. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2020028454","journal-title":"Crit Rev Eukaryot Gene Expr"},{"issue":"3","key":"2403_CR5","first-page":"163","volume":"27","author":"L Lugovi\u0107-Mihi\u0107","year":"2019","unstructured":"Lugovi\u0107-Mihi\u0107 L, \u0106esi\u0107 D, Vukovi\u0107 P, Novak Bili\u0107 G, \u0160itum M, \u0160poljar S (2019) Melanoma development: current knowledge on Melanoma pathogenesis. Acta Dermatovenerol Croat 27(3):163\u2013168","journal-title":"Acta Dermatovenerol Croat"},{"issue":"7","key":"2403_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s11912-022-01257-5","volume":"24","author":"RS Seedor","year":"2022","unstructured":"Seedor RS, Orloff M (2022) Treatment of metastatic melanoma in the elderly. Curr Oncol Rep 24(7):825\u2013833. https:\/\/doi.org\/10.1007\/s11912-022-01257-5","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"2403_CR7","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/DAD.0b013e31828a2ec5","volume":"36","author":"O Abbas","year":"2014","unstructured":"Abbas O, Miller DD, Bhawan J (2014) Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol 36(5):363\u2013379. https:\/\/doi.org\/10.1097\/DAD.0b013e31828a2ec5","journal-title":"Am J Dermatopathol"},{"key":"2403_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-0716-1205-7_1","volume":"2265","author":"RK Gregg","year":"2021","unstructured":"Gregg RK (2021) Model systems for the study of malignant melanoma. Methods Mol Biol 2265:1\u201321. https:\/\/doi.org\/10.1007\/978-1-0716-1205-7_1","journal-title":"Methods Mol Biol"},{"issue":"6","key":"2403_CR9","first-page":"1005","volume":"28","author":"M Rastrelli","year":"2014","unstructured":"Rastrelli M, Tropea S, Rossi CR, Alaibac M (2014) Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 28(6):1005\u20131011","journal-title":"In Vivo"},{"issue":"4","key":"2403_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.pop.2015.07.006","volume":"42","author":"MA Linares","year":"2015","unstructured":"Linares MA, Zakaria A, Nizran P (2015) Skin cancer. Prim Care 42(4):645\u2013659. https:\/\/doi.org\/10.1016\/j.pop.2015.07.006","journal-title":"Prim Care"},{"issue":"12","key":"2403_CR11","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1200\/JCO.2006.06.0442","volume":"25","author":"LA Fecher","year":"2007","unstructured":"Fecher LA, Cummings SD, Keefe MJ, Alani RM (2007) Toward a molecular classification of melanoma. J Clin Oncol 25(12):1606\u20131620. https:\/\/doi.org\/10.1200\/JCO.2006.06.0442","journal-title":"J Clin Oncol"},{"key":"2403_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.bbi.2024.02.001","volume":"117","author":"A Oladapo","year":"2024","unstructured":"Oladapo A, Jackson T, Menolascino J, Periyasamy P (2024) Role of pyroptosis in the pathogenesis of various neurological diseases. Brain Behav Immun 117:428\u2013446. https:\/\/doi.org\/10.1016\/j.bbi.2024.02.001","journal-title":"Brain Behav Immun"},{"key":"2403_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101781","volume":"69","author":"SO Vasudevan","year":"2023","unstructured":"Vasudevan SO, Behl B, Rathinam VA (2023) Pyroptosis-induced inflammation and tissue damage. Semin Immunol 69:101781. https:\/\/doi.org\/10.1016\/j.smim.2023.101781","journal-title":"Semin Immunol"},{"issue":"4","key":"2403_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167301","volume":"434","author":"Y Wei","year":"2022","unstructured":"Wei Y, Yang L, Pandeya A, Cui J, Zhang Y, Li Z (2022) Pyroptosis-induced inflammation and tissue damage. J Mol Biol 434(4):167301. https:\/\/doi.org\/10.1016\/j.jmb.2021.167301","journal-title":"J Mol Biol"},{"issue":"4","key":"2403_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167379","volume":"434","author":"Y Hu","year":"2022","unstructured":"Hu Y, Wang B, Li S, Yang S (2022) Pyroptosis, and its role in central nervous system disease. J Mol Biol 434(4):167379. https:\/\/doi.org\/10.1016\/j.jmb.2021.167379","journal-title":"J Mol Biol"},{"key":"2403_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cca.2022.04.011","volume":"531","author":"Z Cao","year":"2022","unstructured":"Cao Z, Huang D, Tang C, Lu Y, Huang S, Peng C, Hu X (2022) Pyroptosis in diabetes and diabetic nephropathy. Clin Chim Acta 531:188\u2013196. https:\/\/doi.org\/10.1016\/j.cca.2022.04.011","journal-title":"Clin Chim Acta"},{"key":"2403_CR17","doi-asserted-by":"publisher","first-page":"6686617","DOI":"10.1155\/2021\/6686617","volume":"2021","author":"KJ Zhang","year":"2021","unstructured":"Zhang KJ, Wu Q, Jiang SM, Ding L, Liu CX, Xu M, Wang Y, Zhou Y, Li L (2021) Pyroptosis: a new frontier in kidney diseases. Oxid Med Cell Longev 2021:6686617. https:\/\/doi.org\/10.1155\/2021\/6686617","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"2403_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01932-z","volume":"22","author":"Z Liu","year":"2024","unstructured":"Liu Z, Xu S, Chen L, Gong J, Wang M (2024) The role of pyroptosis in cancer: key components and therapeutic potential. Cell Commun Signal 22(1):548. https:\/\/doi.org\/10.1186\/s12964-024-01932-z","journal-title":"Cell Commun Signal"},{"issue":"9","key":"2403_CR19","doi-asserted-by":"publisher","first-page":"4310","DOI":"10.7150\/thno.71086","volume":"12","author":"Z Rao","year":"2022","unstructured":"Rao Z, Zhu Y, Yang P, Chen Z, Xia Y, Qiao C, Liu W, Deng H, Li J, Ning P, Wang Z (2022) Pyroptosis in inflammatory diseases and cancer. Theranostics 12(9):4310\u20134329. https:\/\/doi.org\/10.7150\/thno.71086","journal-title":"Theranostics"},{"issue":"9","key":"2403_CR20","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","volume":"11","author":"BE Burdette","year":"2021","unstructured":"Burdette BE, Esparza AN, Zhu H, Wang S (2021) Gasdermin D in pyroptosis. Acta Pharm Sin B 11(9):2768\u20132782. https:\/\/doi.org\/10.1016\/j.apsb.2021.02.006","journal-title":"Acta Pharm Sin B"},{"key":"2403_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109595","volume":"121","author":"Y Fang","year":"2020","unstructured":"Fang Y, Tian S, Pan Y, Li W, Wang Q, Tang Y, Yu T, Wu X, Shi Y, Ma P, Shu Y (2020) Pyroptosis: a new frontier in cancer. Biomed Pharmacother 121:109595. https:\/\/doi.org\/10.1016\/j.biopha.2019.109595","journal-title":"Biomed Pharmacother"},{"key":"2403_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101263","volume":"101","author":"Y Sun","year":"2024","unstructured":"Sun Y, Li F, Liu Y, Qiao D, Yao X, Liu GS, Li D, Xiao C, Wang T, Chi W (2024) Targeting inflammasomes and pyroptosis in retinal diseases-molecular mechanisms and future perspectives. Prog Retin Eye Res 101:101263. https:\/\/doi.org\/10.1016\/j.preteyeres.2024.101263","journal-title":"Prog Retin Eye Res"},{"issue":"3-4","key":"2403_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10495-022-01807-z","volume":"28","author":"X Li","year":"2023","unstructured":"Li X, Ji L, Men X, Chen X, Zhi M, He S, Chen S (2023) Pyroptosis in bone loss. Apoptosis 28(3\u20134):293\u2013312. https:\/\/doi.org\/10.1007\/s10495-022-01807-z","journal-title":"Apoptosis"},{"issue":"3","key":"2403_CR24","doi-asserted-by":"publisher","first-page":"300","DOI":"10.23736\/S2784-8671.21.06958-3","volume":"156","author":"M Bobos","year":"2021","unstructured":"Bobos M (2021) Histopathologic classification and prognostic factors of melanoma: a 2021 update. Ital J Dermatol Venerol 156(3):300\u2013321. https:\/\/doi.org\/10.23736\/S2784-8671.21.06958-3","journal-title":"Ital J Dermatol Venerol"},{"issue":"4","key":"2403_CR25","doi-asserted-by":"publisher","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","volume":"144","author":"DE Elder","year":"2018","unstructured":"Elder DE, Bastian BC, Cree IA, Massi D, Scolyer RA (2018) The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma: detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144(4):500\u2013522. https:\/\/doi.org\/10.5858\/arpa.2019-0561-RA","journal-title":"Arch Pathol Lab Med"},{"issue":"3-4","key":"2403_CR26","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10555-011-9306-z","volume":"30","author":"K M\u00fcller-Decker","year":"2011","unstructured":"M\u00fcller-Decker K (2011) Cyclooxygenase-dependent signaling is causally linked to non-melanoma skin carcinogenesis: pharmacological, genetic, and clinical evidence. Cancer Metastasis Rev 30(3\u20134):343\u2013361. https:\/\/doi.org\/10.1007\/s10555-011-9306-z","journal-title":"Cancer Metastasis Rev"},{"issue":"2","key":"2403_CR27","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1152\/physiol.00022.2019","volume":"35","author":"B Briard","year":"2020","unstructured":"Briard B, Place DE, Kanneganti TD (2020) DNA sensing in the innate immune response. Physiol 35(2):112\u2013124. https:\/\/doi.org\/10.1152\/physiol.00022.2019","journal-title":"Physiol"},{"issue":"9","key":"2403_CR28","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.3390\/cells10092320","volume":"10","author":"C Teixido","year":"2021","unstructured":"Teixido C, Castillo P, Martinez-Vila C, Arance A, Alos L (2021) Molecular markers and targets in melanoma. Cells 10(9):2320. https:\/\/doi.org\/10.3390\/cells10092320","journal-title":"Cells"},{"issue":"1","key":"2403_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00827-6","volume":"6","author":"W Guo","year":"2021","unstructured":"Guo W, Wang H, Li C (2021) Signal pathways of melanoma and targeted therapy. Signal Transduct Target Ther 6(1):424. https:\/\/doi.org\/10.1038\/s41392-021-00827-6","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2403_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.coms.2021.12.001","volume":"34","author":"AM Bunnell","year":"2022","unstructured":"Bunnell AM, Nedrud SM, Fernandes RP (2022) Classification and staging of melanoma in the head and neck. Oral Maxillofac Surg Clin North Am 34(2):221\u2013234. https:\/\/doi.org\/10.1016\/j.coms.2021.12.001","journal-title":"Oral Maxillofac Surg Clin North Am"},{"issue":"2","key":"2403_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/s1085-5629(97)80005-3","volume":"16","author":"M Brown","year":"1997","unstructured":"Brown M (1997) Staging and prognosis of melanoma. Semin Cutan Med Surg 16(2):113\u2013121. https:\/\/doi.org\/10.1016\/s1085-5629(97)80005-3","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"2403_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.det.2022.07.017","volume":"41","author":"S Rashid","year":"2023","unstructured":"Rashid S, Shaughnessy M, Tsao H (2023) Melanoma classification and management in the era of molecular medicine. Dermatol Clin 41(1):49\u201363. https:\/\/doi.org\/10.1016\/j.det.2022.07.017","journal-title":"Dermatol Clin"},{"issue":"8","key":"2403_CR33","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA (2018) Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol 29(8):1861\u20131868. https:\/\/doi.org\/10.1093\/annonc\/mdy226","journal-title":"Ann Oncol"},{"issue":"8","key":"2403_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0666-x","volume":"20","author":"M Wada-Ohno","year":"2019","unstructured":"Wada-Ohno M, Ito T, Furue M (2019) Adjuvant therapy for melanoma. Curr Treat Options Oncol 20(8):63. https:\/\/doi.org\/10.1007\/s11864-019-0666-x","journal-title":"Curr Treat Options Oncol"},{"issue":"26","key":"2403_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202402208","volume":"11","author":"X Liu","year":"2024","unstructured":"Liu X, Shen M, Bing T, Zhang X, Li Y, Cai Q, Yang X, Yu Y (2024) A bioactive injectable hydrogel regulates tumor metastasis and wound healing for melanoma via NIR-light triggered hyperthermia. Adv Sci 11(26):e2402208. https:\/\/doi.org\/10.1002\/advs.202402208","journal-title":"Adv Sci"},{"issue":"19","key":"2403_CR36","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebb\u00e9 C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA (2017) CheckMate 238 collaborators adjuvant nivolumab versus Ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824\u20131835. https:\/\/doi.org\/10.1056\/NEJMoa1709030","journal-title":"N Engl J Med"},{"issue":"19","key":"2403_CR37","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Schadendorf D, Lesimple T, Plummer R, Ji R, Zhang P, Mookerjee B, Legos J, Kefford R, Dummer R, Kirkwood JM (2017) Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377(19):1813\u20131823. https:\/\/doi.org\/10.1056\/NEJMoa1708539","journal-title":"N Engl J Med"},{"key":"2403_CR38","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejca.2023.03.011","volume":"186","author":"AHR Varey","year":"2023","unstructured":"Varey AHR, Thompson JF, Howle JR, Lo SN, Ch\u2019ng S, Carlino MS (2023) Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary? Eur J Cancer 186:166\u2013171. https:\/\/doi.org\/10.1016\/j.ejca.2023.03.011","journal-title":"Eur J Cancer"},{"issue":"5","key":"2403_CR39","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","volume":"16","author":"AM Eggermont","year":"2015","unstructured":"Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebb\u00e9 C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522\u2013530. https:\/\/doi.org\/10.1016\/S1470-2045(15)70122-1","journal-title":"Lancet Oncol"},{"issue":"7","key":"2403_CR40","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1002\/cncr.21760","volume":"106","author":"S Verma","year":"2006","unstructured":"Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N (2006) Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer 106(7):1431\u20131442. https:\/\/doi.org\/10.1002\/cncr.21760","journal-title":"Cancer"},{"issue":"14","key":"2403_CR41","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/cncr.34806","volume":"129","author":"MJ Mooradian","year":"2023","unstructured":"Mooradian MJ, Sullivan RJ (2023) The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma. Cancer 129(14):2117\u20132121. https:\/\/doi.org\/10.1002\/cncr.34806","journal-title":"Cancer"},{"issue":"4","key":"2403_CR42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","volume":"34","author":"JM Versluis","year":"2023","unstructured":"Versluis JM, Menzies AM, Sikorska K, Rozeman EA, Saw RPM, van Houdt WJ, Eriksson H, Klop WMC, Ch\u2019ng S, van Thienen JV, Mallo H, Gonzalez M, Torres Acosta A, Grijpink-Ongering LG, van der Wal A, Bruining A, van de Wiel BA, Scolyer RA, Haanen JBAG, Schumacher TN, van Akkooi ACJ, Long GV, Blank CU (2023) Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 34(4):420\u2013430. https:\/\/doi.org\/10.1016\/j.annonc.2023.01.004","journal-title":"Ann Oncol"},{"issue":"9","key":"2403_CR43","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1245\/s10434-022-11761-4","volume":"29","author":"MD Moncrieff","year":"2022","unstructured":"Moncrieff MD, Lo SN, Scolyer RA, Heaton MJ, Nobes JP, Snelling AP, Carr MJ, Nessim C, Wade R, Peach AH, Kisyova R, Mason J, Wilson ED, Nolan G, Pritchard Jones R, Sondak VK, Thompson JF, Zager JS (2022) Evaluation of the indications for sentinel node biopsy in early-stage melanoma with the advent of adjuvant systemic therapy: an international, multicenter study. Ann Surg Oncol 29(9):5937\u20135945. https:\/\/doi.org\/10.1245\/s10434-022-11761-4","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"2403_CR44","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ctrv.2007.06.004","volume":"33","author":"P Lui","year":"2007","unstructured":"Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR (2007) Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev 33(8):665\u2013680. https:\/\/doi.org\/10.1016\/j.ctrv.2007.06.004","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2403_CR45","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/cam4.732","volume":"5","author":"S Yun","year":"2016","unstructured":"Yun S, Vincelette ND, Green MR, Wahner Hendrickson AE, Abraham I (2016) Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials. Cancer Med 5(7):1481\u20131491. https:\/\/doi.org\/10.1002\/cam4.732","journal-title":"Cancer Med"},{"issue":"10","key":"2403_CR46","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1111\/cas.15059","volume":"112","author":"L Li","year":"2021","unstructured":"Li L, Jiang M, Qi L, Wu Y, Song D, Gan J, Li Y, Bai Y (2021) Pyroptosis, a new bridge to tumor immunity. Cancer Sci 112(10):3979\u20133994. https:\/\/doi.org\/10.1111\/cas.15059","journal-title":"Cancer Sci"},{"issue":"12","key":"2403_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"J Chesney","year":"2022","unstructured":"Chesney J, Lewis KD, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan GQ, Kirkwood JM, Hassel JC, Orloff M, Larkin J, Weber J, Furness AJS, Khushalani NI, Medina T, Egger ME, Graf Finckenstein F, Jagasia M, Hari P, Sulur S, Shi W, Wu X, Sarnaik A (2022) Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer 10(12):e005755. https:\/\/doi.org\/10.1136\/jitc-2022-005755","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2403_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-03891-4","volume":"21","author":"D Liu","year":"2023","unstructured":"Liu D, Yang F, Zhang T, Mao R (2023) Leveraging a cuproptosis-based signature to predict the prognosis and drug sensitivity of cutaneous melanoma. J Transl Med 21(1):57. https:\/\/doi.org\/10.1186\/s12967-023-03891-4","journal-title":"J Transl Med"},{"issue":"1","key":"2403_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04513-9","volume":"21","author":"S Zhao","year":"2023","unstructured":"Zhao S, Zhu Y, Liu H, He X, Xie J (2023) System analysis based on the pyroptosis-related genes identifes GSDMD as a novel therapy target for skin cutaneous melanoma. J Transl Med 21(1):801. https:\/\/doi.org\/10.1186\/s12967-023-04513-9","journal-title":"J Transl Med"},{"issue":"3","key":"2403_CR50","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00105-018-4124-7","volume":"69","author":"J Sirokay-Kohlmeyer","year":"2018","unstructured":"Sirokay-Kohlmeyer J (2018) Aktuelle Aspekte in der Prognose des fortgeschrittenen Melanoms Current aspects in the prognosis of advanced melanoma. Hautarzt 69(3):249\u2013259. https:\/\/doi.org\/10.1007\/s00105-018-4124-7","journal-title":"Hautarzt"},{"issue":"3","key":"2403_CR51","doi-asserted-by":"publisher","first-page":"349","DOI":"10.23736\/S0392-0488.18.05970-9","volume":"153","author":"M Berger","year":"2018","unstructured":"Berger M, Richtig G, Kashofer K, Aigelsreiter A, Richtig E (2018) The window of opportunities for targeted therapy in BRAFwt\/NRASwt\/KITwt melanoma: biology and clinical implications of fusion proteins and other mutations. G Ital Dermatol Venereol 153(3):349\u2013360. https:\/\/doi.org\/10.23736\/S0392-0488.18.05970-9","journal-title":"G Ital Dermatol Venereol"},{"issue":"7","key":"2403_CR52","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/j.1610-0387.2011.07603.x","volume":"9","author":"L Held","year":"2011","unstructured":"Held L, Eigentler TK, Meier F, Held M, R\u00f6cken M, Garbe C, Bauer J (2011) Oncogenetics of melanoma: basis for molecular diagnostics and therapy. JDDG J Dtsch Dermatol Ges 9(7):510\u2013516. https:\/\/doi.org\/10.1111\/j.1610-0387.2011.07603.x","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"8","key":"2403_CR53","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","volume":"6","author":"PL Chen","year":"2016","unstructured":"Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA (2016) Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov 6(8):827\u2013837. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-1545","journal-title":"Cancer Discov"},{"issue":"18","key":"2403_CR54","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1517\/14656566.2013.849244","volume":"14","author":"JJ Luke","year":"2013","unstructured":"Luke JJ, Ott PA (2013) Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic? Expert Opin Pharmacother 14(18):2457\u20132462. https:\/\/doi.org\/10.1517\/14656566.2013.849244","journal-title":"Expert Opin Pharmacother"},{"issue":"6322","key":"2403_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli T, Uno H, Wooten EC, Elledge SJ (2017) Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355(6322):eaaf8399. https:\/\/doi.org\/10.1126\/science.aaf8399","journal-title":"Science"},{"issue":"8","key":"2403_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1608132","volume":"8","author":"H Chen","year":"2019","unstructured":"Chen H, Yang M, Wang Q, Song F, Li X, Chen K (2019) The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma. Oncoimmunology 8(8):1608132. https:\/\/doi.org\/10.1080\/2162402X.2019.1608132","journal-title":"Oncoimmunology"},{"issue":"17","key":"2403_CR57","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.1517\/14656566.2011.629187","volume":"12","author":"XY Wang","year":"2011","unstructured":"Wang XY, Zuo D, Sarkar D, Fisher PB (2011) Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma. Expert Opin Pharmacother 12(17):2695\u20132706. https:\/\/doi.org\/10.1517\/14656566.2011.629187","journal-title":"Expert Opin Pharmacother"},{"key":"2403_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110092","volume":"118","author":"L Lu","year":"2023","unstructured":"Lu L, Risch E, Halaban R, Zhen P, Bacchiocchi A, Risch HA (2023) Dynamic changes of circulating soluble PD-1\/PD-L1 and its association with patient survival in immune checkpoint blockade-treated melanoma. Int Immunopharmacol 118:110092. https:\/\/doi.org\/10.1016\/j.intimp.2023.110092","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"2403_CR59","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1001\/jamaoncol.2022.7753","volume":"9","author":"LA Bolte","year":"2023","unstructured":"Bolte LA, Lee KA, Bj\u00f6rk JR, Leeming ER, Campmans-Kuijpers MJE, de Haan JJ, Vila AV, Maltez-Thomas A, Segata N, Board R, Harries M, Lorigan P, de Vries EGE, Nathan P, Fehrmann R, Bataille V, Spector TD, Hospers GAP, Weersma RK (2023) Association of a Mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma. JAMA Oncol 9(5):705\u2013709. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7753","journal-title":"JAMA Oncol"},{"issue":"7559","key":"2403_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF (2015) Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature 523(7559):231\u2013235. https:\/\/doi.org\/10.1038\/nature14404","journal-title":"Nature"},{"issue":"7","key":"2403_CR61","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1039\/c5mb00101c","volume":"11","author":"T Ersahin","year":"2015","unstructured":"Ersahin T, Tuncbag N, Cetin-Atalay R (2015) The PI3K\/AKT\/mTOR interactive pathway. Mol Biosyst 11(7):1946\u20131954. https:\/\/doi.org\/10.1039\/c5mb00101c","journal-title":"Mol Biosyst"},{"issue":"20","key":"2403_CR62","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J, Ascierto PA, Dr\u00e9no B, Atkinson V, Liszkay G, Maio M, Mandal\u00e0 M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Sovak MA, Chang I, Choong N, Hack SP, McArthur GA, Ribas A (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867\u20131876. https:\/\/doi.org\/10.1056\/NEJMoa1408868","journal-title":"N Engl J Med"},{"key":"2403_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2024.117674","volume":"102","author":"H Fujita","year":"2024","unstructured":"Fujita H, Arai S, Arakawa H, Hamamoto K, Kato T, Arai T, Nitta N, Hotta K, Hosokawa N, Ohbayashi T, Takahashi C, Inokuma Y, Tamai I, Yano S, Kunishima M, Watanabe Y (2024) Drug-drug conjugates of MEK and Akt inhibitors for RAS-mutant cancers. Bioorg Med Chem 102:117674. https:\/\/doi.org\/10.1016\/j.bmc.2024.117674","journal-title":"Bioorg Med Chem"},{"issue":"1","key":"2403_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L (2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther 8(1):198. https:\/\/doi.org\/10.1038\/s41392-023-01460-1","journal-title":"Signal Transduct Target Ther"},{"key":"2403_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.680407","volume":"12","author":"L Mao","year":"2021","unstructured":"Mao L, Qi Z, Zhang L, Guo J, Si L (2021) Immunotherapy in acral and mucosal melanoma: current status and future directions. Front Immunol 12:680407. https:\/\/doi.org\/10.3389\/fimmu.2021.680407","journal-title":"Front Immunol"},{"issue":"1","key":"2403_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2394252","volume":"20","author":"H Liu","year":"2024","unstructured":"Liu H, Gou X, Tan Y, Fan Q, Chen J (2024) Immunotherapy and delivery systems for melanoma. Hum Vaccin Immunother 20(1):2394252. https:\/\/doi.org\/10.1080\/21645515.2024.2394252","journal-title":"Hum Vaccin Immunother"},{"issue":"24","key":"2403_CR67","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.21.00079","volume":"39","author":"DJ Olson","year":"2021","unstructured":"Olson DJ, Eroglu Z, Brockstein B, Poklepovic AS, Bajaj M, Babu S, Hallmeyer S, Velasco M, Lutzky J, Higgs E, Bao R, Carll TC, Labadie B, Krausz T, Zha Y, Karrison T, Sondak VK, Gajewski TF, Khushalani NI, Luke JJ (2021) Pembrolizumab plus ipilimumab following anti-PD-1\/L1 failure in melanoma. J Clin Oncol 39(24):2647\u20132655. https:\/\/doi.org\/10.1200\/JCO.21.00079","journal-title":"J Clin Oncol"},{"issue":"8","key":"2403_CR68","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.32604\/or.2025.063843","volume":"33","author":"W Luo","year":"2025","unstructured":"Luo W, Song D, He Y, Song J, Ding Y (2025) Tumor vaccines for malignant melanoma: progress, challenges, and future directions. Oncol Res 33(8):1875\u20131893. https:\/\/doi.org\/10.32604\/or.2025.063843","journal-title":"Oncol Res"},{"issue":"4","key":"2403_CR69","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.cps.2021.05.001","volume":"48","author":"WW Dzwierzynski","year":"2021","unstructured":"Dzwierzynski WW (2021) Melanoma risk factors and prevention. Clin Plast Surg 48(4):543\u2013550. https:\/\/doi.org\/10.1016\/j.cps.2021.05.001","journal-title":"Clin Plast Surg"},{"issue":"6","key":"2403_CR70","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1053\/j.seminoncol.2007.09.013","volume":"34","author":"PB Chapman","year":"2007","unstructured":"Chapman PB (2007) Melanoma vaccines. Semin Oncol 34(6):516\u2013523. https:\/\/doi.org\/10.1053\/j.seminoncol.2007.09.013","journal-title":"Semin Oncol"},{"issue":"1","key":"2403_CR71","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2022.2158670","volume":"19","author":"Q Yin","year":"2023","unstructured":"Yin Q, Zhao N, Chang Y, Dong M, Xu M, Xu W, Jin HF, Liu W, Xu N (2023) Melanoma stem cell vaccine induces effective tumor immunity against melanoma. Hum Vaccin Immunother 19(1):2158670. https:\/\/doi.org\/10.1080\/21645515.2022.2158670","journal-title":"Hum Vaccin Immunother"},{"issue":"2","key":"2403_CR72","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1002\/jcb.21473","volume":"102","author":"L Vujanovic","year":"2007","unstructured":"Vujanovic L, Butterfield LH (2007) Melanoma cancer vaccines and anti-tumor T cell responses. J Cell Biochem 102(2):301\u2013310. https:\/\/doi.org\/10.1002\/jcb.21473","journal-title":"J Cell Biochem"},{"issue":"1","key":"2403_CR73","doi-asserted-by":"publisher","first-page":"7211","DOI":"10.1038\/s41467-023-42881-4","volume":"14","author":"J Adamik","year":"2023","unstructured":"Adamik J, Munson PV, Maurer DM, Hartmann FJ, Bendall SC, Arg\u00fcello RJ, Butterfield LH (2023) Immuno-metabolic dendritic cell vaccine signatures associate with overall survival in vaccinated melanoma patients. Nat Commun 14(1):7211. https:\/\/doi.org\/10.1038\/s41467-023-42881-4","journal-title":"Nat Commun"},{"issue":"4","key":"2403_CR74","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4067\/S0716-97602013000400014","volume":"46","author":"F Salazar-Onfray","year":"2013","unstructured":"Salazar-Onfray F, Pereda C, Reyes D, L\u00f3pez MN (2013) TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer. Biol Res 46(4):431\u2013440. https:\/\/doi.org\/10.4067\/S0716-97602013000400014","journal-title":"Biol Res"},{"issue":"4","key":"2403_CR75","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s1470-2045(00)00290-4","volume":"2","author":"JD Wolchok","year":"2001","unstructured":"Wolchok JD, Livingston PO (2001) Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol 2(4):205\u2013211. https:\/\/doi.org\/10.1016\/s1470-2045(00)00290-4","journal-title":"Lancet Oncol"},{"issue":"3","key":"2403_CR76","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/00002371-200005000-00011","volume":"23","author":"SW Lee","year":"2000","unstructured":"Lee SW, Li H, Strong TV, Moore SE, Conry RM (2000) Development of a polynucleotide vaccine from melanoma antigen recognized by T cells-1 and recombinant protein from melanoma antigen recognized by T cells-1 for melanoma vaccine clinical trials. J Immunother 23(3):379\u2013386. https:\/\/doi.org\/10.1097\/00002371-200005000-00011","journal-title":"J Immunother"},{"issue":"2","key":"2403_CR77","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4049\/jimmunol.154.2.730","volume":"154","author":"DS Hoon","year":"1995","unstructured":"Hoon DS, Yuzuki D, Hayashida M, Morton DL (1995) Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol 154(2):730\u2013737","journal-title":"J Immunol"},{"issue":"1","key":"2403_CR78","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-024-01102-w","volume":"32","author":"HC Liao","year":"2025","unstructured":"Liao HC, Liu SJ (2025) Advances in nucleic acid-based cancer vaccines. J Biomed Sci 32(1):10. https:\/\/doi.org\/10.1186\/s12929-024-01102-w","journal-title":"J Biomed Sci"},{"issue":"7","key":"2403_CR79","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/s41551-022-01000-2","volume":"7","author":"MH Teplensky","year":"2023","unstructured":"Teplensky MH, Evangelopoulos M, Dittmar JW, Forsyth CM, Sinegra AJ, Wang S, Mirkin CA (2023) Multi-antigen spherical nucleic acid cancer vaccines. Nat Biomed Eng 7(7):911\u2013927. https:\/\/doi.org\/10.1038\/s41551-022-01000-2","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"2403_CR80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1158\/2159-8290.CD-NB2023-0082","volume":"14","author":"Personalized DNA Vaccine Immunogenic Against Melanoma","year":"2024","unstructured":"Personalized DNA Vaccine Immunogenic Against Melanoma (2024) Cancer Discov 14(1):8\u20139. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2023-0082","journal-title":"Cancer Discov"},{"issue":"19","key":"2403_CR81","doi-asserted-by":"publisher","first-page":"5125","DOI":"10.1016\/j.cell.2025.06.019","volume":"188","author":"E Blass","year":"2025","unstructured":"Blass E, Keskin DB, Tu CR, Forman C, Vanasse A, Sax HE, Shim B, Chea V, Kim N, Carulli I, Southard J, Lyu H, Lu W, Rickles-Young M, Afeyan AB, Olive O, Mehndiratta A, Greenslade H, Shetty K, Baginska J, Gomez Diaz I, Nau A, Pfaff KL, Gans A, Ranasinghe S, Buchbinder EI, Sussman TA, Insco ML, Yoon CH, Rodig SJ, Shukla SA, Li S, Aster JC, Braun DA, Cibulskis C, Hacohen N, Neuberg DS, Giobbie-Hurder A, Livak KJ, Fritsch EF, Oliveira G, Simon JM, Wu CJ, Ott PA (2025) A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma. Cell 188(19):5125-5141.e27. https:\/\/doi.org\/10.1016\/j.cell.2025.06.019","journal-title":"Cell"},{"issue":"7662","key":"2403_CR82","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ (2017) An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547(7662):217\u2013221. https:\/\/doi.org\/10.1038\/nature22991","journal-title":"Nature"},{"issue":"11","key":"2403_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116001","volume":"23","author":"MC Gelmi","year":"2022","unstructured":"Gelmi MC, Houtzagers LE, Strub T, Krossa I, Jager MJ (2022) MITF in normal melanocytes, cutaneous and uveal melanoma: a delicate balance. Int J Mol Sci 23(11):6001. https:\/\/doi.org\/10.3390\/ijms23116001","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2403_CR84","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.1158\/1078-0432.CCR-17-0010","volume":"23","author":"M Ennen","year":"2017","unstructured":"Ennen M, Keime C, Gambi G, Kieny A, Coassolo S, Thibault-Carpentier C, Margerin-Schaller F, Davidson G, Vagne C, Lipsker D, Davidson I (2017) MITF-High and MITF-Low cells and a novel subpopulation expressing genes of both cell states contribute to intra- and intertumoral heterogeneity of primary melanoma. Clin Cancer Res 23(22):7097\u20137107. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0010","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2403_CR85","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","volume":"72","author":"ML Hartman","year":"2015","unstructured":"Hartman ML, Czyz M (2015) MITF in melanoma: mechanisms behind its expression and activity. Cell Mol Life Sci 72(7):1249\u20131260. https:\/\/doi.org\/10.1007\/s00018-014-1791-0","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"2403_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25126532","volume":"25","author":"R Reschke","year":"2024","unstructured":"Reschke R, Enk AH, Hassel JC (2024) Chemokines and cytokines in immunotherapy of melanoma and other tumors: from biomarkers to therapeutic targets. Int J Mol Sci 25(12):6532. https:\/\/doi.org\/10.3390\/ijms25126532","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2403_CR87","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01064-4","volume":"23","author":"SE Bentebibel","year":"2021","unstructured":"Bentebibel SE, Diab A (2021) Cytokines in the treatment of melanoma. Curr Oncol Rep 23(7):83. https:\/\/doi.org\/10.1007\/s11912-021-01064-4","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"2403_CR88","doi-asserted-by":"publisher","first-page":"239S","DOI":"10.1038\/jid.1993.83","volume":"100","author":"C Garbe","year":"1993","unstructured":"Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100(2):239S\u2013244S","journal-title":"J Invest Dermatol"},{"issue":"5","key":"2403_CR89","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2217\/imt.11.45","volume":"3","author":"C Nicholas","year":"2011","unstructured":"Nicholas C, Lesinski GB (2011) Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy 3(5):673\u2013690. https:\/\/doi.org\/10.2217\/imt.11.45","journal-title":"Immunotherapy"},{"issue":"2","key":"2403_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021601","volume":"24","author":"SM Hossain","year":"2023","unstructured":"Hossain SM, Eccles MR (2023) Phenotype switching and the melanoma microenvironment; impact on immunotherapy and drug resistance. Int J Mol Sci 24(2):1601. https:\/\/doi.org\/10.3390\/ijms24021601","journal-title":"Int J Mol Sci"},{"issue":"9","key":"2403_CR91","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/s41423-021-00740-6","volume":"18","author":"Y Huang","year":"2021","unstructured":"Huang Y, Xu W, Zhou R (2021) NLRP3 inflammasome activation and cell death. Cell Mol Immunol 18(9):2114\u20132127. https:\/\/doi.org\/10.1038\/s41423-021-00740-6","journal-title":"Cell Mol Immunol"},{"key":"2403_CR92","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jare.2020.08.004","volume":"28","author":"A Al Mamun","year":"2020","unstructured":"Al Mamun A, Wu Y, Monalisa I, Jia C, Zhou K, Munir F, Xiao J (2020) Role of pyroptosis in spinal cord injury and its therapeutic implications. J Adv Res 28:97\u2013109. https:\/\/doi.org\/10.1016\/j.jare.2020.08.004","journal-title":"J Adv Res"},{"issue":"1","key":"2403_CR93","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/imr.12909","volume":"297","author":"M Zheng","year":"2020","unstructured":"Zheng M, Kanneganti TD (2020) The regulation of the ZBP1-NLRP3 inflammasome and its implications in pyroptosis, apoptosis, and necroptosis (PANoptosis). Immunol Rev 297(1):26\u201338. https:\/\/doi.org\/10.1111\/imr.12909","journal-title":"Immunol Rev"},{"key":"2403_CR94","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/2782112","author":"S Xue","year":"2022","unstructured":"Xue S, Xue Y, Dou D, Wu H, Zhang P, Gao Y, Tang Y, Xia Z, Yang S, Gu S (2022) Kui Jie Tong ameliorates ulcerative colitis by regulating gut microbiota and NLRP3\/Caspase-1 classical pyroptosis signaling pathway. Dis Markers. https:\/\/doi.org\/10.1155\/2022\/2782112","journal-title":"Dis Markers"},{"issue":"1-2","key":"2403_CR95","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/17534259221143216","volume":"29","author":"X Ouyang","year":"2023","unstructured":"Ouyang X, Zhou J, Lin L, Zhang Z, Luo S, Hu D (2023) Pyroptosis, inflammasome, and gasdermins in tumor immunity. Innate Immun 29(1\u20132):3\u201313. https:\/\/doi.org\/10.1177\/17534259221143216","journal-title":"Innate Immun"},{"issue":"10","key":"2403_CR96","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.7150\/ijbs.60292","volume":"17","author":"H Yan","year":"2021","unstructured":"Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, Ke X, Wu J, Yuan J (2021) Cisplatin induces pyroptosis via activation of MEG3\/NLRP3\/caspase-1\/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci 17(10):2606\u20132621. https:\/\/doi.org\/10.7150\/ijbs.60292","journal-title":"Int J Biol Sci"},{"issue":"3","key":"2403_CR97","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1093\/bjd\/ljad421","volume":"190","author":"L Calabrese","year":"2024","unstructured":"Calabrese L, Fiocco Z, Mellett M, Aoki R, Rubegni P, French LE, Satoh TK (2024) Role of the NLRP1 inflammasome in skin cancer and inflammatory skin diseases. Br J Dermatol 190(3):305\u2013315. https:\/\/doi.org\/10.1093\/bjd\/ljad421","journal-title":"Br J Dermatol"},{"issue":"13","key":"2403_CR98","doi-asserted-by":"publisher","first-page":"4166","DOI":"10.7150\/ijbs.86855","volume":"19","author":"H Huang","year":"2023","unstructured":"Huang H, Weng Y, Tian W, Lin X, Chen J, Luo L (2023) Molecular mechanisms of pyroptosis and its role in anti-tumor immunity. Int J Biol Sci 19(13):4166\u20134180. https:\/\/doi.org\/10.7150\/ijbs.86855","journal-title":"Int J Biol Sci"},{"key":"2403_CR99","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01197","volume":"9","author":"Q Guo","year":"2018","unstructured":"Guo Q, Wu Y, Hou Y, Liu Y, Liu T, Zhang H, Fan C, Guan H, Li Y, Shan Z, Teng W (2018) Cytokine secretion and pyroptosis of thyroid follicular cells mediated by enhanced NLRP3, NLRP1, NLRC4, and AIM2 inflammasomes are associated with autoimmune thyroiditis. Front Immunol 9:1197. https:\/\/doi.org\/10.3389\/fimmu.2018.01197","journal-title":"Front Immunol"},{"issue":"20","key":"2403_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202204031","volume":"19","author":"Y Xing","year":"2023","unstructured":"Xing Y, Zhang F, Ji P, Wei M, Yin C, Yang A, Yang G, Zhao J (2023) Efficient delivery of GSDMD-N mRNA by engineered extracellular vesicles induces pyroptosis for enhanced immunotherapy. Small 19(20):e2204031. https:\/\/doi.org\/10.1002\/smll.202204031","journal-title":"Small"},{"issue":"8","key":"2403_CR101","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41581-019-0158-z","volume":"15","author":"T Komada","year":"2019","unstructured":"Komada T, Muruve DA (2019) The role of inflammasomes in kidney disease. Nat Rev Nephrol 15(8):501\u2013520. https:\/\/doi.org\/10.1038\/s41581-019-0158-z","journal-title":"Nat Rev Nephrol"},{"key":"2403_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1093985","volume":"13","author":"J Ju","year":"2023","unstructured":"Ju J, Liu Y, Liang H, Yang B (2023) The role of pyroptosis in endothelial dysfunction induced by diseases. Front Immunol 13:1093985. https:\/\/doi.org\/10.3389\/fimmu.2022.1093985","journal-title":"Front Immunol"},{"issue":"7","key":"2403_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/biom12071010","volume":"12","author":"H Zhao","year":"2022","unstructured":"Zhao H, Yang Y, Si X, Liu H, Wang H (2022) The role of pyroptosis and autophagy in ischemia reperfusion injury. Biomolecules 12(7):1010. https:\/\/doi.org\/10.3390\/biom12071010","journal-title":"Biomolecules"},{"key":"2403_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105408","volume":"165","author":"J Wu","year":"2021","unstructured":"Wu J, Sun J, Meng X (2021) Pyroptosis by caspase-11 inflammasome-Gasdermin D pathway in autoimmune diseases. Pharmacol Res 165:105408. https:\/\/doi.org\/10.1016\/j.phrs.2020.105408","journal-title":"Pharmacol Res"},{"key":"2403_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1364911","volume":"15","author":"L Chao","year":"2024","unstructured":"Chao L, Zhang W, Feng Y, Gao P, Ma J (2024) Pyroptosis: a new insight into intestinal inflammation and cancer. Front Immunol 15:1364911. https:\/\/doi.org\/10.3389\/fimmu.2024.1364911","journal-title":"Front Immunol"},{"issue":"11","key":"2403_CR106","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/j.cell.2023.04.025","volume":"186","author":"KC Barnett","year":"2023","unstructured":"Barnett KC, Li S, Liang K, Ting JP (2023) A 360\u00b0 view of the inflammasome: mechanisms of activation, cell death, and diseases. Cell 186(11):2288\u20132312. https:\/\/doi.org\/10.1016\/j.cell.2023.04.025","journal-title":"Cell"},{"key":"2403_CR107","doi-asserted-by":"publisher","first-page":"6145","DOI":"10.2147\/IJGM.S367693","volume":"15","author":"AA Li","year":"2022","unstructured":"Li AA, Zhang Y, Tong WL, Chen JW, Huang SH, Liu JM, Liu ZL (2022) Identification of a novel pyroptosis-related gene signature indicative of disease prognosis and treatment response in skin cutaneous melanoma. Int J Gen Med 15:6145\u20136163. https:\/\/doi.org\/10.2147\/IJGM.S367693","journal-title":"Int J Gen Med"},{"issue":"1","key":"2403_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02344-4","volume":"24","author":"C Huang","year":"2025","unstructured":"Huang C, Li J, Wu R, Li Y, Zhang C (2025) Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives. Mol Cancer 24(1):131. https:\/\/doi.org\/10.1186\/s12943-025-02344-4","journal-title":"Mol Cancer"},{"issue":"8","key":"2403_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1761-4","volume":"10","author":"L Sun","year":"2019","unstructured":"Sun L, Ma W, Gao W, Xing Y, Chen L, Xia Z, Zhang Z, Dai Z (2019) Propofol directly induces caspase-1-dependent macrophage pyroptosis through the NLRP3-ASC inflammasome. Cell Death Dis 10(8):542. https:\/\/doi.org\/10.1038\/s41419-019-1761-4","journal-title":"Cell Death Dis"},{"issue":"6","key":"2403_CR110","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4166\/kjg.2011.58.6.300","volume":"58","author":"JM Kim","year":"2011","unstructured":"Kim JM (2011) [Inflammatory bowel diseases and inflammasome]. Korean J Gastroenterol 58(6):300\u2013310. https:\/\/doi.org\/10.4166\/kjg.2011.58.6.300","journal-title":"Korean J Gastroenterol"},{"issue":"1","key":"2403_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-025-00249-8","volume":"6","author":"Y Li","year":"2025","unstructured":"Li Y, Guo B (2025) GSDMD-mediated pyroptosis: molecular mechanisms, diseases and therapeutic targets. Mol Biomed 6(1):11. https:\/\/doi.org\/10.1186\/s43556-025-00249-8","journal-title":"Mol Biomed"},{"issue":"9","key":"2403_CR112","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.tcb.2017.05.005","volume":"27","author":"SB Kovacs","year":"2017","unstructured":"Kovacs SB, Miao EA (2017) Gasdermins: effectors of pyroptosis. Trends Cell Biol 27(9):673\u2013684. https:\/\/doi.org\/10.1016\/j.tcb.2017.05.005","journal-title":"Trends Cell Biol"},{"key":"2403_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2023.101803","volume":"69","author":"HC Huston","year":"2023","unstructured":"Huston HC, Anderson MJ, Fink SL (2023) Pyroptosis and the cellular consequences of gasdermin pores. Semin Immunol 69:101803. https:\/\/doi.org\/10.1016\/j.smim.2023.101803","journal-title":"Semin Immunol"},{"key":"2403_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2022.101587","volume":"65","author":"C Huang","year":"2022","unstructured":"Huang C, Li J, Zhang C (2022) What role does pyroptosis play in cancer? Mol Metab 65:101587. https:\/\/doi.org\/10.1016\/j.molmet.2022.101587","journal-title":"Mol Metab"},{"issue":"10","key":"2403_CR115","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1007\/s11864-023-01119-7","volume":"24","author":"T Lyu","year":"2023","unstructured":"Lyu T, Yin Q (2023) Research progress on pyroptosis in hematological malignancies. Curr Treat Options Oncol 24(10):1439\u20131450. https:\/\/doi.org\/10.1007\/s11864-023-01119-7","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2403_CR116","doi-asserted-by":"publisher","DOI":"10.3390\/nu17030461","volume":"17","author":"B Yang","year":"2025","unstructured":"Yang B, Qi Z, Armas Diaz Y, Cassotta M, Grosso G, Cianciosi D, Zhang D, Zou X, Quiles JL, Battino M, Giampieri F (2025) Pyroptosis: a novel therapeutic target for bioactive compounds in human disease treatment? A narrative review. Nutrients 17(3):461. https:\/\/doi.org\/10.3390\/nu17030461","journal-title":"Nutrients"},{"issue":"2019","key":"2403_CR117","doi-asserted-by":"publisher","first-page":"8151836","DOI":"10.1155\/2019\/8151836","volume":"17","author":"Z Qiu","year":"2019","unstructured":"Qiu Z, He Y, Ming H, Lei S, Leng Y, Xia ZY (2019) Lipopolysaccharide (LPS) aggravates high glucose- and hypoxia\/reoxygenation-induced injury through activating ROS-dependent NLRP3 inflammasome-mediated pyroptosis in H9C2 cardiomyocytes. J Diabetes Res 17(2019):8151836. https:\/\/doi.org\/10.1155\/2019\/8151836","journal-title":"J Diabetes Res"},{"issue":"1","key":"2403_CR118","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02516-7","volume":"11","author":"N Miao","year":"2025","unstructured":"Miao N, Kang Z, Wang Z, Yu W, Liu T, Kong LZ, Zheng Y, Ding C, Zhang Z, Zhong C, Fang Q, Li K (2025) Mitochondrial reactive oxygen species promote cancer metastasis and tumor microenvironment immunosuppression through gasdermin D. Cell Death Discov 11(1):219. https:\/\/doi.org\/10.1038\/s41420-025-02516-7","journal-title":"Cell Death Discov"},{"issue":"4","key":"2403_CR119","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21041456","volume":"21","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Li G (2020) Mechanisms and therapeutic regulation of pyroptosis in inflammatory diseases and cancer. Int J Mol Sci 21(4):1456. https:\/\/doi.org\/10.3390\/ijms21041456","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2403_CR120","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.492","volume":"11","author":"T Du","year":"2021","unstructured":"Du T, Gao J, Li P, Wang Y, Qi Q, Liu X, Li J, Wang C, Du L (2021) Pyroptosis, metabolism, and tumor immune microenvironment. Clin Transl Med 11(8):e492. https:\/\/doi.org\/10.1002\/ctm2.492","journal-title":"Clin Transl Med"},{"issue":"1","key":"2403_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02183-9","volume":"23","author":"H Wang","year":"2024","unstructured":"Wang H, Wang T, Yan S, Tang J, Zhang Y, Wang L, Xu H, Tu C (2024) Crosstalk of pyroptosis and cytokine in the tumor microenvironment: from mechanisms to clinical implication. Mol Cancer 23(1):268. https:\/\/doi.org\/10.1186\/s12943-024-02183-9","journal-title":"Mol Cancer"},{"issue":"4","key":"2403_CR122","doi-asserted-by":"publisher","first-page":"260","DOI":"10.14715\/cmb\/2024.70.4.41","volume":"70","author":"R Attar","year":"2024","unstructured":"Attar R, Qureshi MZ, Sabitaliyevich UY, Yulaevna IM, Romero MA (2024) Mechanistic role of pyroptosis in tumor microenvironment and tumor immunotherapy. Cell Mol Biol 70(4):260\u2013267. https:\/\/doi.org\/10.14715\/cmb\/2024.70.4.41","journal-title":"Cell Mol Biol"},{"key":"2403_CR123","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.biochi.2021.03.007","volume":"185","author":"X Ju","year":"2021","unstructured":"Ju X, Yang Z, Zhang H, Wang Q (2021) Role of pyroptosis in cancer cells and clinical applications. Biochimie 185:78\u201386. https:\/\/doi.org\/10.1016\/j.biochi.2021.03.007","journal-title":"Biochimie"},{"key":"2403_CR124","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116295","volume":"268","author":"H Hu","year":"2024","unstructured":"Hu H, Zhang F, Sheng Z, Tian S, Li G, Tang S, Niu Y, Yang J, Liu Y (2024) Synthesis and mitochondria-localized iridium (III) complexes induce cell death through pyroptosis and ferroptosis pathways. Eur J Med Chem 268:116295. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116295","journal-title":"Eur J Med Chem"},{"issue":"1","key":"2403_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-022-01194-z","volume":"15","author":"C Liu","year":"2022","unstructured":"Liu C, Liu Y, Yu Y, Zhao Y, Yu A (2022) Comprehensive analysis of ferroptosis-related genes and prognosis of cutaneous melanoma. BMC Med Genomics 15(1):39. https:\/\/doi.org\/10.1186\/s12920-022-01194-z","journal-title":"BMC Med Genomics"},{"issue":"1","key":"2403_CR126","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01545-6","volume":"17","author":"S Zhou","year":"2024","unstructured":"Zhou S, Liu J, Wan A, Zhang Y, Qi X (2024) Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis. J Hematol Oncol 17(1):22. https:\/\/doi.org\/10.1186\/s13045-024-01545-6","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2403_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02217-2","volume":"24","author":"P Zhao","year":"2025","unstructured":"Zhao P, Yin S, Qiu Y, Sun C, Yu H (2025) Ferroptosis and pyroptosis are connected through autophagy: a new perspective of overcoming drug resistance. Mol Cancer 24(1):23. https:\/\/doi.org\/10.1186\/s12943-024-02217-2","journal-title":"Mol Cancer"},{"issue":"21","key":"2403_CR128","doi-asserted-by":"publisher","first-page":"24379","DOI":"10.18632\/aging.203687","volume":"13","author":"J Meng","year":"2021","unstructured":"Meng J, Huang X, Qiu Y, Zheng X, Huang J, Wen Z, Yao J (2021) Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. Aging 13(21):24379\u201324401. https:\/\/doi.org\/10.18632\/aging.203687","journal-title":"Aging"},{"issue":"5","key":"2403_CR129","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/PAT.0b013e328363b3bd","volume":"45","author":"JM Brandner","year":"2013","unstructured":"Brandner JM, Haass NK (2013) Melanoma\u2019s connections to the tumour microenvironment. Pathology 45(5):443\u2013452. https:\/\/doi.org\/10.1097\/PAT.0b013e328363b3bd","journal-title":"Pathology"},{"issue":"36","key":"2403_CR130","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030564","volume":"101","author":"Z Shi","year":"2022","unstructured":"Shi Z, Gu J, Yao Y, Wu Z (2022) Identification of a predictive gene signature related to pyroptosis for the prognosis of cutaneous melanoma. Medicine 101(36):e30564. https:\/\/doi.org\/10.1097\/MD.0000000000030564","journal-title":"Medicine"},{"key":"2403_CR131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.709077","volume":"11","author":"A Ju","year":"2021","unstructured":"Ju A, Tang J, Chen S, Fu Y, Luo Y (2021) Pyroptosis-related gene signatures can robustly diagnose skin cutaneous melanoma and predict the prognosis. Front Oncol 11:709077. https:\/\/doi.org\/10.3389\/fonc.2021.709077","journal-title":"Front Oncol"},{"issue":"6","key":"2403_CR132","doi-asserted-by":"publisher","first-page":"353","DOI":"10.21037\/atm-22-1095","volume":"10","author":"YY Wang","year":"2022","unstructured":"Wang YY, Shi LY, Zhu ZT, Wang QJ (2022) A new pyroptosis model can predict the immunotherapy response and immune microenvironment characteristics and prognosis of patients with cutaneous melanoma based on TCGA and GEO databases. Ann Transl Med 10(6):353. https:\/\/doi.org\/10.21037\/atm-22-1095","journal-title":"Ann Transl Med"},{"issue":"11","key":"2403_CR133","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1097\/IAE.0000000000002732","volume":"40","author":"CB Toomey","year":"2020","unstructured":"Toomey CB, Protopsaltis NJ, Phou S, Bakhoum MF, Thorson JA, Ediriwickrema LS, Korn BS, Kikkawa DO, Goldbaum MH, Lin JH (2020) Prevalence of mismatch repair gene mutations in uveal melanoma. Retina 40(11):2216\u20132220. https:\/\/doi.org\/10.1097\/IAE.0000000000002732","journal-title":"Retina"},{"key":"2403_CR134","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.758981","volume":"12","author":"Z Xu","year":"2021","unstructured":"Xu Z, Xie Y, Mao Y, Huang J, Mei X, Song J, Sun Y, Yao Z, Shi W (2021) Ferroptosis-related gene signature predicts the prognosis of skin cutaneous melanoma and response to immunotherapy. Front Genet 12:758981. https:\/\/doi.org\/10.3389\/fgene.2021.758981","journal-title":"Front Genet"},{"key":"2403_CR135","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/3827999","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Han D, Duan H, Rao Q, Qian Y, Chen Q, Du X, Ni H, Wang S (2023) Identification of pyroptosis-relevant signature in tumor immune microenvironment and prognosis in skin cutaneous melanoma using network analysis. Stem Cells Int. https:\/\/doi.org\/10.1155\/2023\/3827999","journal-title":"Stem Cells Int"},{"issue":"1","key":"2403_CR136","doi-asserted-by":"publisher","first-page":"688","DOI":"10.3934\/mbe.2022031","volume":"19","author":"Z Niu","year":"2022","unstructured":"Niu Z, Xu Y, Li Y, Chen Y, Han Y (2022) Construction and validation of a novel pyroptosis-related signature to predict prognosis in patients with cutaneous melanoma. Math Biosci Eng 19(1):688\u2013706. https:\/\/doi.org\/10.3934\/mbe.2022031","journal-title":"Math Biosci Eng"},{"issue":"9","key":"2403_CR137","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.immuni.2021.08.019","volume":"54","author":"AK Molodtsov","year":"2021","unstructured":"Molodtsov AK, Khatwani N, Vella JL, Lewis KA, Zhao Y, Han J, Sullivan DE, Searles TG, Preiss NK, Shabaneh TB, Zhang P, Hawkes AR, Malik BT, Kolling FW 4th, Usherwood EJ, Wong SL, Phillips JD, Shirai K, Angeles CV, Yan S, Curiel TJ, Huang YH, Cheng C, Turk MJ (2021) Resident memory CD8+ T cells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity 54(9):2117-2132.e7. https:\/\/doi.org\/10.1016\/j.immuni.2021.08.019","journal-title":"Immunity"},{"issue":"3","key":"2403_CR138","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41588-025-02077-6","volume":"57","author":"L Liang","year":"2025","unstructured":"Liang L, Kuang X, He Y, Zhu L, Lau P, Li X, Luo D, Gong L, Zhou W, Zhang F, Liang X, Li Z, Hu B, Liu D, Ding T, Li H, Zhao S, Su J, Hung MC, Liu J, Liu H, Chen X (2025) Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma. Nat Genet 57(3):680\u2013693. https:\/\/doi.org\/10.1038\/s41588-025-02077-6","journal-title":"Nat Genet"},{"issue":"3","key":"2403_CR139","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031119","volume":"23","author":"H Nanamori","year":"2022","unstructured":"Nanamori H, Sawada Y (2022) Epigenetic modification of PD-1\/PD-L1-mediated cancer immunotherapy against melanoma. Int J Mol Sci 23(3):1119. https:\/\/doi.org\/10.3390\/ijms23031119","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2403_CR140","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/bjd\/ljad333","volume":"190","author":"N Pandeya","year":"2023","unstructured":"Pandeya N, Dusingize JC, Olsen CM, MacGregor S, Neale RE, Law MH, Whiteman DC (2023) Does genetic risk modify the effect of skin screening on melanoma detection rates? Br J Dermatol 190(1):37\u201344. https:\/\/doi.org\/10.1093\/bjd\/ljad333","journal-title":"Br J Dermatol"},{"issue":"1","key":"2403_CR141","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-24879-y","volume":"12","author":"B Zhou","year":"2022","unstructured":"Zhou B, Sha S, Tao J, Li J, Shen C, Zhu J, Tan L, Dong L, Huang C (2022) The expression pattern of pyroptosis-related genes predicts the prognosis and drug response of melanoma. Sci Rep 12(1):21566. https:\/\/doi.org\/10.1038\/s41598-022-24879-y","journal-title":"Sci Rep"},{"issue":"2","key":"2403_CR142","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-06366-y","volume":"15","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Bai Y, Ma XX, Song JK, Luo Y, Fei XY, Ru Y, Luo Y, Jiang JS, Zhang Z, Yang D, Xue TT, Zhang HP, Liu TY, Xiang YW, Kuai L, Liu YQ, Li B (2024) Correction: clinical-mediated discovery of pyroptosis in CD8+ T cell and NK cell reveals melanoma heterogeneity by single-cell and bulk sequence. Cell Death Dis 15(2):164. https:\/\/doi.org\/10.1038\/s41419-023-06366-y","journal-title":"Cell Death Dis"},{"issue":"8","key":"2403_CR143","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1111\/febs.17204","volume":"292","author":"M Zouali","year":"2025","unstructured":"Zouali M (2025) Swaying the advantage: multifaceted functions of inflammasomes in adaptive immunity. FEBS J 292(8):1817\u20131832. https:\/\/doi.org\/10.1111\/febs.17204","journal-title":"FEBS J"},{"issue":"11","key":"2403_CR144","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1016\/j.immuni.2023.10.004","volume":"56","author":"R Miao","year":"2023","unstructured":"Miao R, Jiang C, Chang WY, Zhang H, An J, Ho F, Chen P, Zhang H, Junqueira C, Amgalan D, Liang FG, Zhang J, Evavold CL, Hafner-Bratkovi\u010d I, Zhang Z, Fontana P, Xia S, Waldeck-Weiermair M, Pan Y, Michel T, Bar-Peled L, Wu H, Kagan JC, Kitsis RN, Zhang P, Liu X, Lieberman J (2023) Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis. Immunity 56(11):2523-2541.e8. https:\/\/doi.org\/10.1016\/j.immuni.2023.10.004","journal-title":"Immunity"},{"issue":"Pt A","key":"2403_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108270","volume":"101","author":"S Qiu","year":"2021","unstructured":"Qiu S, Hu Y, Dong S (2021) Pan-cancer analysis reveals the expression, genetic alteration and prognosis of pyroptosis key gene GSDMD. Int Immunopharmacol 101(Pt A):108270. https:\/\/doi.org\/10.1016\/j.intimp.2021.108270","journal-title":"Int Immunopharmacol"},{"issue":"47","key":"2403_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202410336","volume":"11","author":"H Yin","year":"2024","unstructured":"Yin H, Chen T, Hu X, Zhu W, Li Y, Sun W, Li L, Zhang H, Wang Q (2024) Pyroptosis-inducing biomaterials pave the way for transformative antitumor immunotherapy. Adv Sci 11(47):e2410336. https:\/\/doi.org\/10.1002\/advs.202410336","journal-title":"Adv Sci"},{"issue":"1","key":"2403_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03175-0","volume":"22","author":"W Chen","year":"2024","unstructured":"Chen W, He Y, Zhou G, Chen X, Ye Y, Zhang G, Liu H (2024) Multiomics characterization of pyroptosis in the tumor microenvironment and therapeutic relevance in metastatic melanoma. BMC Med 22(1):24. https:\/\/doi.org\/10.1186\/s12916-023-03175-0","journal-title":"BMC Med"},{"key":"2403_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1062225","volume":"13","author":"M Khan","year":"2022","unstructured":"Khan M, Ai M, Du K, Song J, Wang B, Lin J, Ren A, Chen C, Huang Z, Qiu W, Zhang J, Tian Y, Yuan Y (2022) Pyroptosis relates to tumor microenvironment remodeling and prognosis: a pan-cancer perspective. Front Immunol 13:1062225. https:\/\/doi.org\/10.3389\/fimmu.2022.1062225","journal-title":"Front Immunol"},{"issue":"31","key":"2403_CR149","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202404375","volume":"11","author":"H Ren","year":"2024","unstructured":"Ren H, Wu Z, Tan J, Tao H, Zou W, Cao Z, Wen B, Cai Z, Du J, Deng Z (2024) Co-delivery nano system of MS-275 and V-9302 induces pyroptosis and enhances anti-tumor immunity against uveal melanoma. Adv Sci 11(31):e2404375. https:\/\/doi.org\/10.1002\/advs.202404375","journal-title":"Adv Sci"},{"issue":"4","key":"2403_CR150","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, Gao W, Shao F (2017) Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 42(4):245\u2013254. https:\/\/doi.org\/10.1016\/j.tibs.2016.10.004","journal-title":"Trends Biochem Sci"},{"issue":"19","key":"2403_CR151","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.2147\/IJN.S457309","volume":"10","author":"F Ji","year":"2024","unstructured":"Ji F, Shi C, Shu Z, Li Z (2024) Nanomaterials enhance pyroptosis-based tumor immunotherapy. Int J Nanomedicine 10(19):5545\u20135579. https:\/\/doi.org\/10.2147\/IJN.S457309","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"2403_CR152","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/j.devcel.2025.02.005","volume":"60","author":"N Zhang","year":"2025","unstructured":"Zhang N, Xu D (2025) Controlling pyroptosis through post-translational modifications of gasdermin D. Dev Cell 60(7):994\u20131007. https:\/\/doi.org\/10.1016\/j.devcel.2025.02.005","journal-title":"Dev Cell"},{"issue":"10","key":"2403_CR153","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1016\/j.jid.2025.03.021","volume":"145","author":"L Su","year":"2025","unstructured":"Su L, Wang D, Purwin TJ, Ran S, Yang Q, Zhang Q, Cai W (2025) Selective USP7 inhibition synergizes with MEK1\/2 inhibitor to enhance immune responses and potentiate anti-PD-1 therapy in NRAS-mutant melanoma. J Invest Dermatol 145(10):2549-2561.e11. https:\/\/doi.org\/10.1016\/j.jid.2025.03.021","journal-title":"J Invest Dermatol"},{"issue":"7791","key":"2403_CR154","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita R, Lauss M, Sanna A, Donia M, Skaarup Larsen M, Mitra S, Johansson I, Phung B, Harbst K, Vallon-Christersson J, van Schoiack A, L\u00f6vgren K, Warren S, Jirstr\u00f6m K, Olsson H, Pietras K, Ingvar C, Isaksson K, Schadendorf D, Schmidt H, Bastholt L, Carneiro A, Wargo JA, Svane IM, J\u00f6nsson G (2020) Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791):561\u2013565. https:\/\/doi.org\/10.1038\/s41586-019-1914-8","journal-title":"Nature"},{"issue":"23","key":"2403_CR155","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133103","volume":"4","author":"LF de Andrade","year":"2019","unstructured":"de Andrade LF, Lu Y, Luoma A, Ito Y, Pan D, Pyrdol JW, Yoon CH, Yuan GC, Wucherpfennig KW (2019) Discovery of specialized NK cell populations infiltrating human melanoma metastases. JCI Insight 4(23):e133103. https:\/\/doi.org\/10.1172\/jci.insight.133103","journal-title":"JCI Insight"},{"issue":"7-9","key":"2403_CR156","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1089\/ars.2023.0257","volume":"39","author":"Q Cao","year":"2023","unstructured":"Cao Q, Zhang JB, Sun DY, Fu JT, Wu WB, Chen XF, Li DJ, Wang P (2023) Pyroptosis, metabolism, and oxidation in tumorigenesis: mechanisms and therapeutic implications. Antioxid Redox Signal 39(7\u20139):512\u2013530. https:\/\/doi.org\/10.1089\/ars.2023.0257","journal-title":"Antioxid Redox Signal"},{"issue":"4","key":"2403_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111553","volume":"41","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Yang Y, Hu Y, Yang R, Huang J, Liu Y, Wu Y, Li S, Ma C, Humphries F, Wang B, Wang X, Hu Z, Yang S (2022) Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade. Cell Rep 41(4):111553. https:\/\/doi.org\/10.1016\/j.celrep.2022.111553","journal-title":"Cell Rep"},{"key":"2403_CR158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1629620","volume":"16","author":"Z Shan","year":"2025","unstructured":"Shan Z, Liu F (2025) Targeting ferroptosis, pyroptosis and necroptosis for cancer immunotherapy in melanoma: mechanistic insights and clinical perspectives. Front Immunol 16:1629620. https:\/\/doi.org\/10.3389\/fimmu.2025.1629620","journal-title":"Front Immunol"},{"issue":"4","key":"2403_CR159","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.cell.2019.07.019","volume":"178","author":"JL Benci","year":"2019","unstructured":"Benci JL, Johnson LR, Choa R, Xu Y, Qiu J, Zhou Z, Xu B, Ye D, Nathanson KL, June CH, Wherry EJ, Zhang NR, Ishwaran H, Hellmann MD, Wolchok JD, Kambayashi T, Minn AJ (2019) Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178(4):933-948.e14. https:\/\/doi.org\/10.1016\/j.cell.2019.07.019","journal-title":"Cell"},{"issue":"5","key":"2403_CR160","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.4110\/in.2020.20.e39","volume":"20","author":"SM Hong","year":"2020","unstructured":"Hong SM, Lee J, Jang SG, Lee J, Cho ML, Kwok SK, Park SH (2020) Type I interferon increases inflammasomes associated pyroptosis in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome. Immune Net 20(5):e39. https:\/\/doi.org\/10.4110\/in.2020.20.e39","journal-title":"Immune Net"},{"issue":"10","key":"2403_CR161","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1158\/1078-0432.CCR-22-1922","volume":"29","author":"A Betof Warner","year":"2023","unstructured":"Betof Warner A, Corrie PG, Hamid O (2023) Tumor-infiltrating lymphocyte therapy in melanoma: facts to the future. Clin Cancer Res 29(10):1835\u20131854. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-1922","journal-title":"Clin Cancer Res"},{"issue":"6264","key":"2403_CR162","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aac4255","volume":"350","author":"A Sivan","year":"2015","unstructured":"Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Lei YM, Jabri B, Alegre ML, Chang EB, Gajewski TF (2015) Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264):1084\u20131089. https:\/\/doi.org\/10.1126\/science.aac4255","journal-title":"Science"},{"issue":"1","key":"2403_CR163","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.suc.2019.09.013","volume":"100","author":"J Sun","year":"2020","unstructured":"Sun J, Carr MJ, Khushalani NI (2020) Principles of targeted therapy for melanoma. Surg Clin North Am 100(1):175\u2013188. https:\/\/doi.org\/10.1016\/j.suc.2019.09.013","journal-title":"Surg Clin North Am"},{"key":"2403_CR164","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-022-00197-2","volume":"2","author":"X Xiao","year":"2022","unstructured":"Xiao X, Guo Q, Cui C, Lin Y, Zhang L, Ding X, Li Q, Wang M, Yang W, Kong Y, Yu R (2022) Multiplexed imaging mass cytometry reveals distinct tumor-immune microenvironments linked to immunotherapy responses in melanoma. Commun Med 2:131. https:\/\/doi.org\/10.1038\/s43856-022-00197-2","journal-title":"Commun Med"},{"key":"2403_CR165","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1322468","volume":"15","author":"J Yang","year":"2024","unstructured":"Yang J, Jiang J (2024) Gasdermins: a dual role in pyroptosis and tumor immunity. Front Immunol 15:1322468. https:\/\/doi.org\/10.3389\/fimmu.2024.1322468","journal-title":"Front Immunol"},{"issue":"1","key":"2403_CR166","doi-asserted-by":"publisher","first-page":"10801","DOI":"10.1038\/s41467-024-55083-3","volume":"15","author":"S Orehek","year":"2024","unstructured":"Orehek S, Ramuta T\u017d, Lain\u0161\u010dek D, Malen\u0161ek \u0160, \u0160ala M, Ben\u010dina M, Jerala R, Hafner-Bratkovi\u010d I (2024) Cytokine-armed pyroptosis induces antitumor immunity against diverse types of tumors. Nat Commun 15(1):10801. https:\/\/doi.org\/10.1038\/s41467-024-55083-3","journal-title":"Nat Commun"},{"key":"2403_CR167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1672312","volume":"16","author":"A Vall\u00e9e","year":"2025","unstructured":"Vall\u00e9e A, Drezet A, Arutkin M (2025) Pan-cancer convergence of tumour-immune microenvironment motifs revealed by CyTOF and imaging mass cytometry. Front Immunol 16:1672312. https:\/\/doi.org\/10.3389\/fimmu.2025.1672312","journal-title":"Front Immunol"},{"issue":"42","key":"2403_CR168","doi-asserted-by":"publisher","first-page":"7214","DOI":"10.2174\/0929867327666191220103901","volume":"27","author":"LM Khachigian","year":"2020","unstructured":"Khachigian LM (2020) Repurposing drugs for skin cancer. Curr Med Chem 27(42):7214\u20137221. https:\/\/doi.org\/10.2174\/0929867327666191220103901","journal-title":"Curr Med Chem"},{"issue":"4","key":"2403_CR169","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041873","volume":"22","author":"M Song","year":"2021","unstructured":"Song M, Liu C, Chen S, Zhang W (2021) Nanocarrier-based drug delivery for melanoma therapeutics. Int J Mol Sci 22(4):1873. https:\/\/doi.org\/10.3390\/ijms22041873","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2403_CR170","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1021\/acs.molpharmaceut.2c00775","volume":"19","author":"H Wang","year":"2022","unstructured":"Wang H, Tran TT, Duong KT, Nguyen T, Le UM (2022) Options of therapeutics and novel delivery systems of drugs for the treatment of melanoma. Mol Pharm 19(12):4487\u20134505. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00775","journal-title":"Mol Pharm"},{"issue":"7","key":"2403_CR171","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1111\/bcp.14693","volume":"87","author":"E Casarotto","year":"2021","unstructured":"Casarotto E, Noize P, L\u00e9tinier L, Salvo F, Pham-Ledard A, Molimard M (2021) Safety profile of drugs for advanced melanoma: a report based on 2008\u20132018 US food and drug administration data. Br J Clin Pharmacol 87(7):2988\u20132995. https:\/\/doi.org\/10.1111\/bcp.14693","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"2403_CR172","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1517\/13543784.16.9.1459","volume":"16","author":"CC Cunningham","year":"2007","unstructured":"Cunningham CC (2007) Talabostat. Expert Opin Investig Drugs 16(9):1459\u20131465. https:\/\/doi.org\/10.1517\/13543784.16.9.1459","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"2403_CR173","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.critrevonc.2009.08.005","volume":"74","author":"R Mouawad","year":"2010","unstructured":"Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D (2010) Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol 74(1):27\u201339. https:\/\/doi.org\/10.1016\/j.critrevonc.2009.08.005","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"2403_CR174","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1007\/s11095-023-03506-z","volume":"40","author":"S Rahman","year":"2023","unstructured":"Rahman S, Haque TN, Sugandhi VV, Saraswat AL, Xin X, Cho H (2023) Topical cream carrying drug-loaded nanogels for melanoma treatment. Pharm Res 40(10):2291\u20132301. https:\/\/doi.org\/10.1007\/s11095-023-03506-z","journal-title":"Pharm Res"},{"issue":"5","key":"2403_CR175","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1517\/14712598.2014.890586","volume":"14","author":"S Tomei","year":"2014","unstructured":"Tomei S, Wang E, Delogu LG, Marincola FM, Bedognetti D (2014) Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opin Biol Ther 14(5):663\u2013686. https:\/\/doi.org\/10.1517\/14712598.2014.890586","journal-title":"Expert Opin Biol Ther"},{"key":"2403_CR176","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jconrel.2023.04.028","volume":"357","author":"J Kim","year":"2023","unstructured":"Kim J, Archer PA, Manspeaker MP, Avecilla ARC, Pollack BP, Thomas SN (2023) Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma. J Control Release 357:655\u2013668. https:\/\/doi.org\/10.1016\/j.jconrel.2023.04.028","journal-title":"J Control Release"},{"issue":"8","key":"2403_CR177","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1158\/2159-8290.CD-17-0607","volume":"7","author":"RW Jenkins","year":"2017","unstructured":"Jenkins RW, Barbie DA (2017) Refining targeted therapy opportunities for BRAF-mutant melanoma. Cancer Discov 7(8):799\u2013801. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0607","journal-title":"Cancer Discov"},{"issue":"12","key":"2403_CR178","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11912-022-01306-z","volume":"24","author":"JS Choi","year":"2022","unstructured":"Choi JS, Chandra S (2022) Targeted therapy for melanomas without BRAF V600 mutation. Curr Oncol Rep 24(12):1873\u20131881. https:\/\/doi.org\/10.1007\/s11912-022-01306-z","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2403_CR179","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","volume":"187","author":"G Leuzzi","year":"2024","unstructured":"Leuzzi G, Vasciaveo A, Taglialatela A, Chen X, Firestone TM, Hickman AR, Mao W, Thakar T, Vaitsiankova A, Huang JW, Cuella-Martin R, Hayward SB, Kesner JS, Ghasemzadeh A, Nambiar TS, Ho P, Rialdi A, Hebrard M, Li Y, Gao J, Gopinath S, Adeleke OA, Venters BJ, Drake CG, Baer R, Izar B, Guccione E, Keogh MC, Guerois R, Sun L, Lu C, Califano A, Ciccia A (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell 187(4):861-881.e32. https:\/\/doi.org\/10.1016\/j.cell.2024.01.008","journal-title":"Cell"},{"issue":"Pt A","key":"2403_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108344","volume":"101","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Zhang C, Zhang J, Han D, Shi X (2021) Comprehensive analysis of the prognosis and biological significance for IFIT family in skin cutaneous melanoma. Int Immunopharmacol 101(Pt A):108344. https:\/\/doi.org\/10.1016\/j.intimp.2021.108344","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"2403_CR181","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/1541-7786.MCR-24-0508","volume":"23","author":"SD Varney","year":"2025","unstructured":"Varney SD, Erkes DA, Mersky GL, Mustafa MU, Chua V, Chervoneva I, Purwin TJ, Alnemri E, Aplin AE (2025) Metabolic inhibition induces pyroptosis in uveal melanoma. Mol Cancer Res 23(4):350\u2013362. https:\/\/doi.org\/10.1158\/1541-7786.MCR-24-0508","journal-title":"Mol Cancer Res"},{"issue":"1","key":"2403_CR182","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-05599-9","volume":"12","author":"F Zhang","year":"2022","unstructured":"Zhang F, Deng Y, Wang D, Wang S (2022) Construction and validation of a pyroptosis-related gene signature associated with the tumor microenvironment in uveal melanoma. Sci Rep 12(1):1640. https:\/\/doi.org\/10.1038\/s41598-022-05599-9","journal-title":"Sci Rep"},{"key":"2403_CR183","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.761350","volume":"9","author":"Y Cao","year":"2021","unstructured":"Cao Y, Xie J, Chen L, Hu Y, Zhai L, Yuan J, Suo L, Shen Y, Ye R, Li J, Gong Z, Dong Y, Bao W, Li H, Wang M (2021) Construction and validation of a novel pyroptosis-related gene signature to predict the prognosis of uveal melanoma. Front Cell Dev Biol 9:761350. https:\/\/doi.org\/10.3389\/fcell.2021.761350","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"2403_CR184","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1080\/02713683.2022.2048396","volume":"47","author":"S Lei","year":"2022","unstructured":"Lei S, Li H (2022) Two pyroptosis-related subtypes with distinct immune microenvironment characteristics and a novel signature for predicting immunotherapy response and prognosis in uveal melanoma. Curr Eye Res 47(6):930\u2013943. https:\/\/doi.org\/10.1080\/02713683.2022.2048396","journal-title":"Curr Eye Res"},{"issue":"20","key":"2403_CR185","doi-asserted-by":"publisher","first-page":"3138","DOI":"10.1038\/sj.onc.1206454","volume":"22","author":"MS Soengas","year":"2003","unstructured":"Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22(20):3138\u20133151. https:\/\/doi.org\/10.1038\/sj.onc.1206454","journal-title":"Oncogene"},{"issue":"11","key":"2403_CR186","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1038\/s41587-023-01684-0","volume":"41","author":"A Gottschlich","year":"2023","unstructured":"Gottschlich A, Thomas M, Gr\u00fcnmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, M\u00fcller K, Xu T, Dhoqina D, M\u00e4rkl F, Robinson S, Sendelhofert A, Schulz H, Umut \u00d6, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, M\u00fcller PJ, D\u00f6rr J, Seifert M, Cadilha BL, Brabenec R, R\u00f6der N, Rataj F, N\u00fcesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltr\u00e1n E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S (2023) Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nat Biotechnol 41(11):1618\u20131632. https:\/\/doi.org\/10.1038\/s41587-023-01684-0","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2403_CR187","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.semnuclmed.2015.12.005","volume":"46","author":"A Norain","year":"2016","unstructured":"Norain A, Dadachova E (2016) Targeted radionuclide therapy of melanoma. Semin Nucl Med 46(3):250\u2013259. https:\/\/doi.org\/10.1053\/j.semnuclmed.2015.12.005","journal-title":"Semin Nucl Med"},{"issue":"2","key":"2403_CR188","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS (2023) CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematol Malig Rep 18(2):9\u201318. https:\/\/doi.org\/10.1007\/s11899-023-00687-7","journal-title":"Curr Hematol Malig Rep"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10495-026-02403-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-026-02403-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:10:10Z","timestamp":1789672210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10495-026-02403-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,23]]},"references-count":188,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2403"],"URL":"https:\/\/doi.org\/10.1007\/s10495-026-02403-1","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,23]]},"assertion":[{"value":"22 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"214"}}